View Older Stories View More Recent Stories

Jan 9, 2025 09:00AM Exelixis Provides Update on Oncologic Drugs Advisory Committee Meeting for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors
Jan 6, 2025 04:05PM Exelixis to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025
Nov 27, 2024 04:05PM Exelixis to Webcast Fireside Chats as Part of Investor Conferences in December
Nov 26, 2024 04:05PM Exelixis Provides Regulatory Update Related to Supplemental New Drug Application for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors
Nov 7, 2024 04:05PM Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November
Oct 29, 2024 04:05PM Exelixis Announces Third Quarter 2024 Financial Results and Provides Corporate Update
Oct 15, 2024 04:05PM Exelixis to Release Third Quarter 2024 Financial Results on Tuesday, October 29, 2024
Oct 15, 2024 01:57PM Exelixis (EXEL) Announces Update on Second Patent Litigation Trial with MSN Laboratories
Oct 15, 2024 01:57PM Exelixis Announces Update on Second Patent Litigation Trial with MSN Laboratories
Oct 14, 2024 08:02AM Exelixis (EXEL) and Merck (MRK) Sign Clinical Development Collaboration to Evaluate Investigational Zanzalintinib in Combination with KEYTRUDA
Oct 14, 2024 08:00AM Exelixis and Merck Sign Clinical Development Collaboration to Evaluate Investigational Zanzalintinib in Combination with KEYTRUDA® (pembrolizumab) in Head and Neck Cancer and in Combination with WELI
Sep 16, 2024 08:45AM Exelixis (EXEL) Reports Final Results from Phase 3 Pivotal CABINET Study of Cabozantinib
Sep 16, 2024 08:45AM Exelixis Announces Final Results from Phase 3 Pivotal CABINET Study Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2024 and Published in New England Journal of Medicine
Sep 15, 2024 08:45AM Exelixis Presents Final Overall Survival Results from Phase 3 CONTACT-02 Pivotal Study Evaluating Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Castration-Resistant Pro
Aug 28, 2024 04:05PM Exelixis to Webcast Fireside Chats as Part of Investor Conferences in September
Aug 6, 2024 04:05PM Exelixis Announces Second Quarter 2024 Financial Results and Provides Corporate Update
Aug 6, 2024 08:30AM Exelixis (EXEL) Announces FDA Accepted sNDA for Cabozantinib for Patients with Advanced Neuroendocrine Tumors
Aug 6, 2024 08:30AM Exelixis Announces U.S. Food and Drug Administration (FDA) Accepted the Supplemental New Drug Application for Cabozantinib for Patients with Advanced Neuroendocrine Tumors
Jul 23, 2024 04:05PM Exelixis to Release Second Quarter 2024 Financial Results on Tuesday, August 6, 2024
May 28, 2024 04:05PM Exelixis to Present at the William Blair 44th Annual Growth Stock Conference
May 20, 2024 08:03AM Exelixis (EXEL) Settles of CABOMETYX Patent Litigation with Cipla Limited and Cipla USA
May 20, 2024 08:00AM Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA
May 7, 2024 04:05PM Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May
Apr 30, 2024 04:05PM Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update
Apr 16, 2024 04:05PM Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024
Feb 27, 2024 04:05PM Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March
Feb 14, 2024 08:30AM Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
Feb 6, 2024 04:05PM Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update
Feb 1, 2024 04:05PM Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February
Jan 25, 2024 08:00AM Exelixis (EXEL) Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial of Cabozantinib in Combination with Atezolizumab
Jan 25, 2024 08:00AM Exelixis Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU
Jan 23, 2024 04:05PM Exelixis to Release Fourth Quarter and Fiscal Year 2023 Financial Results on Tuesday, February 6, 2024
Jan 22, 2024 05:01PM Bristol-Myers Squibb (BMY) and Exelixis (EXEL) Announce Opdivo with CABOMETYX Demonstrated Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial
Jan 22, 2024 05:00PM Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell
Jan 18, 2024 04:07PM Exelixis (EXEL) Reports EU Patent Office Ruled in Favor of Exelixis on Formulation Patent Covering CABOMETYX
Jan 18, 2024 04:05PM European Patent Office Rules in Favor of Exelixis on Formulation Patent Covering CABOMETYX® (cabozantinib) Tablets
Jan 8, 2024 05:25AM Exelixis (EXEL) Reports Prelim FY23 Results, Issues 2024 Guidance
Jan 7, 2024 04:00PM Exelixis Announces Preliminary Fiscal Year 2023 Financial Results, Provides 2024 Financial Guidance, and Outlines Key Priorities and Milestones for 2024
Jan 2, 2024 04:05PM Exelixis to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024
Dec 7, 2023 04:05PM Exelixis 2023 R&D Day: Science & Strategy to be Webcast on December 12, 2023
Dec 4, 2023 08:03AM Exelixis (EXEL), Arcus Biosciences (RCUS) Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with AB521 in Patients with Advanced Renal Cell Carcinoma
Dec 4, 2023 08:02AM Exelixis Announces Initiation of the STELLAR-305 Phase 2/3 Pivotal Trial Evaluating Zanzalintinib in Combination with Pembrolizumab in Patients with Previously Untreated Recurrent or Metastatic Head a
Dec 4, 2023 08:00AM Exelixis and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with AB521 in Patients with Advanced Renal Cell Carcinoma
Nov 21, 2023 04:05PM Exelixis to Present at the Piper Sandler 35th Annual Healthcare Conference on November 28, 2023
Nov 10, 2023 09:00AM Exelixis (EXEL) Announces Encouraging Results from Expansion Cohort of Phase 1b STELLAR-001 Trial Evaluating Zanzalintinib in Patients with Advanced Kidney Cancer at IKCS 2023
Nov 10, 2023 09:00AM Exelixis Announces Encouraging Results from Expansion Cohort of Phase 1b STELLAR-001 Trial Evaluating Zanzalintinib in Patients with Advanced Kidney Cancer at IKCS 2023
Oct 22, 2023 02:30AM Detailed Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2023
Oct 18, 2023 04:05PM Exelixis to Release Third Quarter 2023 Financial Results on Wednesday, November 1, 2023
Aug 31, 2023 04:05PM Exelixis to Webcast Fireside Chats as Part of Investor Conferences in September
Aug 24, 2023 08:00AM Exelixis (EXEL) Reports Positive Results from Phase 3 CABINET Pivotal Trial of Cabozantinib
View More Recent Stories View Older Stories